- TRADE NAME: Zinplava (Merck)
- INDICATIONS: To reduce the recurrence of Clostridium difficile infection (CDI) in patients who are receiving antibacterial treatment of CDI and are at high risk for CDI recurrence
- CLASS: C. difficile toxin inhibitor, Monoclonal antibody
- HALF-LIFE: ~19 days
- FDA APPROVAL DATE: 10/24/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No data available
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
